HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer - Wikidata - thesis-toulmin - TriplyDB

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

http://www.wikidata.org/entity/Q30837184

about

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice HER2 testing in gastric cancer: An update Companion diagnostics for the targeted therapy of gastric cancer Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab Recent advances in the HER2 targeted therapy of gastric cancer Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer.Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections.HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues.Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.Targeting HER 2 and angiogenesis in gastric cancer.Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer.Pertuzumab in gastrointestinal cancer.Single disease entity for both chromosomal instable subtype gastric adenocarcinoma and esophageal adenocarcinoma.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Esophageal Cancer: New Insights into a Heterogenous Disease.KIF26B, a novel oncogene, promotes proliferation and metastasis by activating the VEGF pathway in gastric cancer.Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.Emerging immunotherapy for the treatment of esophageal cancer.Perspectives of HER2-targeting in gastric and esophageal cancer.Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study.HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.Exosomes participate in the carcinogenesis and the malignant behavior of gastric cancer.Predictive biomarkers along gastric cancer pathogenetic pathways.Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.Role of intravoxel incoherent motion MR imaging in preoperative assessing HER2 status of gastric cancers.Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2.Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study.

P2860

Q26741253-4752064A-56C7-48E2-82D9-4D8CD7D7A524 Q26746253-87AC5C19-AEC2-4AFB-BBA3-1BF0AA97973C Q26780298-C3E29DE0-1C9C-4B8F-825E-28042D864C1F Q28077666-1B76B1EB-D30E-4161-9D69-9A20C4FD44F6 Q33761681-6D812D70-6BBB-4C13-A237-A47B23D10AAE Q34967104-22294802-A358-4526-AEB7-07BD12071155 Q35119526-E2525AC6-782E-4D2D-8A10-A00D5A8B066F Q35831069-A7A742CA-4D76-4BDE-8FEF-F6F7DF9446FE Q36020920-E316002F-4372-4D2A-8178-92E844377892 Q36027093-8F4107B6-7CAC-4EF7-9862-6D4ECFDDC370 Q36303653-42798F84-3856-4A69-AECA-DEA8C3E627FD Q36750684-7E2FBD79-D5A0-4CAA-A733-A1B55ACBF0CD Q36999892-1EB7413A-1689-4512-8120-6CF0B5D1CAFB Q37001973-F4C34E47-7181-4A64-BF3D-A6F31D91B05F Q37708897-D3DDDF3A-3B8A-45E9-83A0-3F270D5B9B9B Q38257364-8C40818D-51A3-40F8-87FB-AC0C865CB73A Q38558734-4F2A28BD-8E7A-4E1C-8F99-E2B3EE876546 Q38633308-BA9CF14D-A434-44A3-8442-AA8CA8B3A38F Q38642021-864D53E5-A1E2-44CA-8A93-A3AF4CDCBB6A Q38653309-D4F702A0-A811-4C95-9AA6-8232A586F434 Q38683298-E99648EB-4EC4-43D4-A539-961915BE4E5B Q38684349-AFF21C56-7104-49AE-A0AB-90A170AB11C4 Q38734003-F5B17B9E-0C3C-41EB-976C-E8C952DA99C5 Q38743870-A09EF65D-D49C-479A-A1E0-95E98A423B5E Q38748208-97485A28-D403-41B7-97E2-C03B87E8CEDC Q38763851-D19400CE-E0F1-407F-B502-AF8DCFC3DAA7 Q38848389-7C869E5D-2F1A-49C5-BC87-263B98C280A1 Q39038994-26540033-CDF4-4456-BCE0-CBE0651484A7 Q39069439-7881C7DE-E5A3-44B1-8965-FA329726E434 Q39080349-A119A95C-7312-4C5D-ABB0-D6815628A3FA Q39106432-71C05986-CDC3-4364-BB23-EA141E896EDF Q39170872-734D0036-135B-4BBD-BB3C-51F8ABEF72C8 Q39441334-4C675558-013C-41B4-B499-77ADDCAEA7A8 Q40417038-72A27D22-E801-45B4-8E31-C9CE53556AB6 Q41472425-3AC063D9-E3B3-4BFB-99DD-9E11176EF394 Q47190729-CEB13212-BD41-4C53-8CB4-F36D3A0400B8 Q47438222-0DE0ECE3-56EC-4246-91AB-275F44151C94 Q47636102-FC11CE3C-7CAF-4161-A370-213D1D82028D Q47932548-ACEECCF3-43B5-4A84-A89D-976D5833D702 Q48340965-FD05D148-C09C-4C99-B5E8-5BC6EB969D7E

P2860

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

http://www.wikidata.org/entity/Q30837184

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@ast

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@en

type

label

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@ast

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@en

prefLabel

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@ast

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@en

P1433

Q30837184-B227E6EA-15BA-42E1-876B-49AA57A12A3C

P1476

Q30837184-F2302D92-9E61-430E-8049-614FBDDA6B45

P2093

Q30837184-085E9137-DB6A-407F-B9DA-6EC34789BD39

Q30837184-1D1904CC-F7CA-4469-88ED-91D3735529AB

Q30837184-29BC1513-8385-4C7A-98DF-311DF8148752

Q30837184-2EA714A1-590C-47FA-A2CC-3CBBEC8590BE

Q30837184-3500061F-9AA0-40A8-B6C3-40BCC7DA3F00

Q30837184-35978FE4-0C5D-45A6-A229-96CD471746C1

Q30837184-3DEBC2F6-39E7-44F0-BCC2-A13CDCD9DF63

Q30837184-42F1EE16-0D4E-41A3-8AC6-AEF5F2297AE2

Q30837184-450AF969-C8CE-4233-B0FB-B40C3F21EC6E

Q30837184-5F5ADFA7-4C49-481C-9A55-8C4DF792C7D3

P2860

Q30837184-0380324A-D734-4938-88A9-C66C834BE02C

Q30837184-09405FF0-F696-41A2-ABD7-B22F5F7AC61E

Q30837184-12CF7EDC-036B-465A-BF68-9F6F5C679AD9

Q30837184-1F1B9DA3-483A-409D-938B-A5D43BE5D81D

Q30837184-209AFAAB-03D4-41E4-8191-D6259AF952DD

Q30837184-28146D91-82E5-45E4-BA69-154EB3926502

Q30837184-2B0F639D-730A-49FD-8E59-DB7704AD1196

Q30837184-312FF11E-0830-4826-BB87-EC1E1C872E06

Q30837184-6350FBBE-13D7-4E81-A467-4456F1A4B109

Q30837184-84155D57-0138-4C5F-9F13-BBBE53DEFA81

P2888

Q30837184-11900533-74BA-4AE3-882C-A66CD0A46EFB

P304

Q30837184-A7D9D846-5043-4614-8B68-9D3D521E8B11

P31

Q30837184-7FBE5975-723E-4119-BC00-62DD4463A217

P356

Q30837184-ABE9AAC6-8DCB-4911-BF27-289D4C7E6F46

P433

Q30837184-3A21B638-6060-463B-A5E0-A2389924BC75

P478

Q30837184-1E5460A8-6DFD-464A-A5E5-52BC81C92415

P50

Q30837184-4A37A328-48BE-4DC0-89AC-D10441E99137

P577

Q30837184-AE4685EF-581D-42C3-8C86-A6A43A1B0C28

P5875

Q30837184-8F37CEF1-2FEC-4827-8C0E-4319D3EFC96D

P6179

Q30837184-6D554CF9-955D-4A3A-8394-E06B062ED732

P698

Q30837184-B93E2364-082B-42FC-A106-FD28DE83F0AA

P932

Q30837184-4FD908D9-0AF3-4C32-8DE6-31261BC9CDA9

P356

S10120-014-0402-Y

P1433

P1476

HER2 screening data from ToGA: ...... stroesophageal junction cancer

@en

P2093

Astrid Kiermaier

http://www.w3.org/2001/XMLSchema#string

Feng Feng-Yi

http://www.w3.org/2001/XMLSchema#string

Jian M Xu

http://www.w3.org/2001/XMLSchema#string

Jorge León Chong

http://www.w3.org/2001/XMLSchema#string

Josef Rüschoff

http://www.w3.org/2001/XMLSchema#string

Julie Hill

http://www.w3.org/2001/XMLSchema#string

Keun-Wook Lee

http://www.w3.org/2001/XMLSchema#string

Marlene Thomas

http://www.w3.org/2001/XMLSchema#string

Michaela Lehle

http://www.w3.org/2001/XMLSchema#string

Oleg Gladkov

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

HER2 testing in gastric cancer: a practical approach

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION

Molecular classification of gastric cancer: a new paradigm.

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

P2888

s10120-014-0402-y

P304

476-484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-014-0402-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Eric Van Cutsem

P577

2014-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264054678

http://www.w3.org/2001/XMLSchema#string

P6179

1047548049

http://www.w3.org/2001/XMLSchema#string

P698

25038874

http://www.w3.org/2001/XMLSchema#string

P932

4511072

http://www.w3.org/2001/XMLSchema#string